By Professor David Thomas

Journal articles

Chantrill LA; Nagrial AM; Watson C; Johns AL; Martyn-Smith M; Simpson S; Mead S; Jones MD; Samra JS; Gill AJ; Watson N; Chin VT; Humphris JL; Chou A; Brown B; Morey A; Pajic M; Grimmond SM; Chang DK; Thomas D; Sebastian L; Sjoquist K; Yip S; Pavlakis N; Asghari R; Harvey S; Grimison P; Simes J; Biankin AV, 2015, 'Precision medicine for advanced pancreas cancer: The individualized molecular pancreatic cancer therapy (IMPaCT) Trial', Clinical Cancer Research, 21, pp. 2029 - 2037, http://dx.doi.org/10.1158/1078-0432.CCR-15-0426

Thomas DM; Wood MA, 2015, 'THE EMERGENCE OF NEGATIVE SUPERHUMPS IN CATACLYSMIC VARIABLES: SMOOTHED PARTICLE HYDRODYNAMICS SIMULATIONS', ASTROPHYSICAL JOURNAL, 803, http://dx.doi.org/10.1088/0004-637X/803/2/55

Wong SQ; Fellowes A; Doig K; Ellul J; Bosma TJ; Irwin D; Vedururu R; Tan AYC; Weiss J; Chan KS; Lucas M; Thomas DM; Dobrovic A; Parisot JP; Fox SB, 2015, 'Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients', British Journal of Cancer, 112, pp. 1411 - 1420, http://dx.doi.org/10.1038/bjc.2015.80

Thomas DM; Ballinger ML, 2015, 'Etiologic, environmental and inherited risk factors in sarcomas', Journal of Surgical Oncology, 111, pp. 490 - 495, http://dx.doi.org/10.1002/jso.23809

Ashley D; Thomas D; Gore L; Carter R; Zalcberg JR; Otmar R; Savulescu J, 2015, 'Accepting risk in the acceleration of drug development for rare cancers', The Lancet Oncology, 16, pp. e190 - e194, http://dx.doi.org/10.1016/S1470-2045(14)71153-2

Tattersall MHN; Thomas DM, 2015, 'Distinguishing activity from progress', The Lancet Oncology, 16, pp. 1586 - 1588, http://dx.doi.org/10.1016/S1470-2045(15)00466-0

Neuhaus SJ; Thomas D; Desai J; Vuletich C; Von Dincklage J; Olver I, 2015, 'Wiki-based clinical practice guidelines for the management of adult onset sarcoma: A new paradigm in sarcoma evidence', Sarcoma, 2015, http://dx.doi.org/10.1155/2015/614179

Lewin J; Khamly KK; Young RJ; Mitchell C; Hicks RJ; Toner GC; Ngan SYK; Chander S; Powell GJ; Herschtal A; Te Marvelde L; Desai J; Choong PFM; Stacker SA; Achen MG; Ferris N; Fox S; Slavin J; Thomas DM, 2014, 'A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma', British Journal of Cancer, 111, pp. 2254 - 2261, http://dx.doi.org/10.1038/bjc.2014.537

Wang Z; Zhu B; Zhang M; Parikh H; Jia J; Chung CC; Sampson JN; Hoskins JW; Hutchinson A; Burdette L; Ibrahim A; Hautman C; Raj PS; Abnet CC; Adjei AA; Ahlbom A; Albanes D; Allen NE; Ambrosone CB; Aldrich M; Amiano P; Amos C; Andersson U; Gerald Andriole GA; Andrulis IL; Arici C; Arslan AA; Austin MA; Baris D; Barkauskas DA; Bassig BA; Freeman LEB; Berg CD; Berndt SI; Bertazzi PA; Biritwum RB; Black A; Blot W; Boeing H; Boffetta P; Bolton K; Boutron-Ruault MC; Bracci PM; Brennan P; Brinton LA; Brotzman M; Bueno-de-Mesquita HB; Buring JE; Butler MA; Cai Q; Cancel-Tassin G; Canzian F; Cao G; Caporaso NE; Carrato A; Carreon T; Carta A; Chang GC; Chang IS; Chang-Claude J; Che X; Chen CJ; Chen CY; Chen CH; Chen C; Chen KY; Chen YM; Chokkalingam AP; Chu LW; Clavel-Chapelon F; Colditz GA; Colt JS; Conti D; Cook MB; Cortessis VK; Crawford ED; Cussenot O; Davis FG; De Vivo I; Deng X; Ding T; Dinney CP; Di Stefano AL; Diver WR; Duell EJ; Elena JW; Fan JH; Feigelson HS; Feychting M; Figueroa JD; Flanagan AM; Fraumeni JF; Freedman ND; Fridley BL; Fuchs CS; Gago-Dominguez M; Gallinger S; Gao YT; Gapstur SM; Garcia-Closas M, 2014, 'Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33', Human Molecular Genetics, 23, pp. 6616 - 6633, http://dx.doi.org/10.1093/hmg/ddu363

Garsed DW; Marshall OJ; Corbin VDA; Hsu A; DiStefano L; Schröder J; Li J; Feng ZP; Kim BW; Kowarsky M; Lansdell B; Brookwell R; Myklebost O; Meza-Zepeda L; Holloway AJ; Pedeutour F; Choo KHA; Damore MA; Deans AJ; Papenfuss AT; Thomas DM, 2014, 'The Architecture and Evolution of Cancer Neochromosomes', Cancer Cell, 26, pp. 653 - 667, http://dx.doi.org/10.1016/j.ccell.2014.09.010

Kansara M; Teng MW; Smyth MJ; Thomas DM, 2014, 'Translational biology of osteosarcoma', Nature Reviews Cancer, 14, pp. 722 - 735, http://dx.doi.org/10.1038/nrc3838

Wong SQ; Li J; Tan AYC; Vedururu R; Pang JMB; Do H; Ellul J; Doig K; Bell A; Macarthur GA; Fox SB; Thomas DM; Fellowes A; Parisot JP; Dobrovic A, 2014, 'Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing', BMC Medical Genomics, 7, http://dx.doi.org/10.1186/1755-8794-7-23

Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM, 2014, 'Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling', Cancer Research, 74, pp. 921 - 931, http://dx.doi.org/10.1158/0008-5472.CAN-13-2424

McBride KA; Ballinger ML; Killick E; Kirk J; Tattersall MHN; Eeles RA; Thomas DM; Mitchell G, 2014, 'Li-Fraumeni syndrome: Cancer risk assessment and clinical management', Nature Reviews Clinical Oncology, 11, pp. 260 - 271, http://dx.doi.org/10.1038/nrclinonc.2014.41

Kansara M; Thomas DM, 2014, 'RB1-mediated cell-autonomous and hostdependent oncosuppressor mechanisms in radiation-induced osteosarcoma', OncoImmunology, 3, http://dx.doi.org/10.4161/onci.27569

Cipponi A; Thomas DM, 2014, 'Stress-induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets', BioEssays, 36, pp. 552 - 560, http://dx.doi.org/10.1002/bies.201300170

Anninga JK; Cleton-Jansen A-M; Hassan B; Amary MF; Baumhoer D; Blay J-Y; Brugieres L; Ferrari S; Jurgens H; Kempf-Bielack B; Kovar H; Myklebost O; Nathrath M; Picci P; Riegman P; Schilham MW; Soliman R; Stark DP; Strauss S; Sydes M; Tarpey P; Thomas D; Whelan J; Wilhelm M; Zamzam M; Gelderblom H; Bielack SS, 2014, 'Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology', CLINICAL SARCOMA RESEARCH, 4, http://dx.doi.org/10.1186/2045-3329-4-4

Bandopadhayay P; Jabbour AM; Riffkin C; Salmanidis M; Gordon L; Popovski D; Rigby L; Ashley DM; Watkins DN; Thomas DM; Algar E; Ekert PG, 2013, 'The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts', BMC Cancer, 13, http://dx.doi.org/10.1186/1471-2407-13-585

Kansara M; Leong HS; Lin DM; Popkiss S; Pang P; Garsed DW; Walkley CR; Cullinane C; Ellul J; Haynes NM; Hicks R; Kuijjer ML; Cleton-Jansen AM; Hinds PW; Smyth MJ; Thomas DM, 2013, 'Immune response to rb1-Regulated senescence limits radiation-Induced osteosarcoma formation', Journal of Clinical Investigation, 123, pp. 5351 - 5360, http://dx.doi.org/10.1172/JCI70559

Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD, 2013, 'Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary', Journal of Pathology, 231, pp. 413 - 423, http://dx.doi.org/10.1002/path.4251

Rossello FJ; Tothill RW; Britt K; Marini KD; Falzon J; Thomas DM; Peacock CD; Marchionni L; Li J; Bennett S; Tantoso E; Brown T; Chan P; Martelotto LG; Watkins DN, 2013, 'Next-Generation Sequence Analysis of Cancer Xenograft Models', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0074432

Doble B; Harris A; Thomas DM; Fox S; Lorgelly P, 2013, 'Multiomics medicine in oncology: Assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual', Pharmacogenomics, 14, pp. 1405 - 1417, http://dx.doi.org/10.2217/pgs.13.142

Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I, 2013, 'Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study', The Lancet Oncology, 14, pp. 901 - 908, http://dx.doi.org/10.1016/S1470-2045(13)70277-8

Mitchell G; Ballinger ML; Wong S; Hewitt C; James P; Young MA; Cipponi A; Pang T; Goode DL; Dobrovic A; Thomas DM; Porceddu S; Gattas M; Neuhaus S; Suthers G; Tattersall M; Tucker K; Lewis C; Carey-Smith R, 2013, 'High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0069026

Collins M; Wilhelm M; Conyers R; Herschtal A; Whelan J; Bielack S; Kager L; Kühne T; Sydes M; Gelderblom H; Ferrari S; Picci P; Smeland S; Eriksson M; Petrilli AS; Bleyer A; Thomas DM, 2013, 'Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: Findings from a meta-analysis', Journal of Clinical Oncology, 31, pp. 2303 - 2312, http://dx.doi.org/10.1200/JCO.2012.43.8598

Cain JE; McCaw A; Jayasekara WSN; Rossello FJ; Marini KD; Irving AT; Kansara M; Thomas DM; Ashley DM; Watkins DN, 2013, 'Sustained low-dose treatment with the Histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells', Sarcoma, 2013, http://dx.doi.org/10.1155/2013/608964

Harvey KF; Zhang X; Thomas DM, 2013, 'The Hippo pathway and human cancer', Nature Reviews Cancer, 13, pp. 246 - 257, http://dx.doi.org/10.1038/nrc3458

Lewin J; Thomas D, 2013, 'Denosumab: A new treatment option for giant cell tumor of bone', Drugs of Today, 49, pp. 693 - 700, http://dx.doi.org/10.1358/dot.2013.49.11.2064725

Savage SA; Mirabello L; Wang Z; Gastier-Foster JM; Gorlick R; Khanna C; Flanagan AM; Tirabosco R; Andrulis IL; Wunder JS; Gokgoz N; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Kurucu N; Ilhan IE; Sari N; Serra M; Hattinger C; Picci P; Spector LG; Barkauskas DA; Marina N; De Toledo SRC; Petrilli AS; Amary MF; Halai D; Thomas DM; Douglass C; Meltzer PS; Jacobs K; Chung CC; Berndt SI; Purdue MP; Caporaso NE; Tucker M; Rothman N; Landi MT; Silverman DT; Kraft P; Hunter DJ; Malats N; Kogevinas M; Wacholder S; Troisi R; Helman L; Fraumeni JF; Yeager M; Hoover RN; Chanock SJ, 2013, 'Genome-wide association study identifies two susceptibility loci for osteosarcoma', Nature Genetics, 45, pp. 799 - 803, http://dx.doi.org/10.1038/ng.2645

Lewin J; Wieringa S; Collins M; Desai J; Orme L; Lingaratnam S; Thomas DM, 2013, 'Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review', CLINICAL SARCOMA RESEARCH, 3, http://dx.doi.org/10.1186/2045-3329-3-15

Lewin J; Puri A; Quek R; Ngan R; Alcasabas AP; Wood D; Thomas D, 2013, 'Management of sarcoma in the asia-pacific region: Resource-stratified guidelines', The Lancet Oncology, 14, pp. e562 - e570, http://dx.doi.org/10.1016/S1470-2045(13)70475-3

Young M-A; Herlihy A; Mitchell G; Thomas DM; Ballinger M; Tucker K; Lewis CR; Neuhaus S; Halliday J, 2013, 'The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research', Clinical Sarcoma Research, 3, pp. 11 - 11, http://dx.doi.org/10.1186/2045-3329-3-11

Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Alex Gaither L; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D, 2012, 'FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective Pan-FGFR inhibitor', Cancer Discovery, 2, pp. 1118 - 1133, http://dx.doi.org/10.1158/2159-8290.CD-12-0210

Paget C; Duret H; Ngiow SF; Kansara M; Thomas DM; Smyth MJ, 2012, 'Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma', OncoImmunology, 1, pp. 1313 - 1322, http://dx.doi.org/10.4161/onci.21680

Kelleher FC; Cain JE; Healy JM; Watkins DN; Thomas DM, 2012, 'Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma', Pharmacology and Therapeutics, 136, pp. 153 - 168, http://dx.doi.org/10.1016/j.pharmthera.2012.08.004

Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I, 2012, 'Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone', Clinical Cancer Research, 18, pp. 4415 - 4424, http://dx.doi.org/10.1158/1078-0432.CCR-12-0578

Ray-Coquard I; Thomas D, 2012, 'Targeted therapies: Pazopanib for soft-tissue sarcoma: A PALETTE of data emerges', Nature Reviews Clinical Oncology, 9, pp. 431 - 432, http://dx.doi.org/10.1038/nrclinonc.2012.113

Pedeutour F; Maire G; Pierron A; Thomas DM; Garsed DW; Bianchini L; Duranton-Tanneur V; Cortes-Maurel A; Italiano A; Squire JA; Coindre JM, 2012, 'A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions', Virchows Archiv, 461, pp. 67 - 78, http://dx.doi.org/10.1007/s00428-012-1256-5

Hubbard J; Thomas DM; Yothers G; Green E; Blanke C; O'Connell MJ; Labianca R; Shi Q; Bleyer A; De Gramont A; Sargent D, 2012, 'Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: Findings from the adjuvant colon cancer endpoints data set', Journal of Clinical Oncology, 30, pp. 2334 - 2339, http://dx.doi.org/10.1200/JCO.2011.41.1975

Thomas DM, 2012, 'RANKL, denosumab, and giant cell tumor of bone', Current Opinion in Oncology, 24, pp. 397 - 403, http://dx.doi.org/10.1097/CCO.0b013e328354c129

Angoa-Perez M; Kane MJ; Briggs DI; Sykes CE; Shah MM; Francescutti DM; Rosenberg DR; Thomas DM; Kuhn DM, 2012, 'Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity', JOURNAL OF NEUROCHEMISTRY, 121, pp. 974 - 984, http://dx.doi.org/10.1111/j.1471-4159.2012.07739.x

Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585

Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; Van Der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY, 2012, 'Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis', Cancer, 118, pp. 1649 - 1655, http://dx.doi.org/10.1002/cncr.26409

Thomas DM; Savage SA; Bond GL, 2012, 'Hereditary and environmental epidemiology of sarcomas', CLINICAL SARCOMA RESEARCH, 2, http://dx.doi.org/10.1186/2045-3329-2-13

Kelleher FC; Thomas DM, 2012, 'Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours', CLINICAL SARCOMA RESEARCH, 2, http://dx.doi.org/10.1186/2045-3329-2-6

Dyson GJ; Thompson K; Palmer S; Thomas DM; Schofield P, 2012, 'The relationship between unmet needs and distress amongst young people with cancer', Supportive Care in Cancer, 20, pp. 75 - 85, http://dx.doi.org/10.1007/s00520-010-1059-7

Blay J; Chawla S; Choy E; Grimer RJ; Ferrari S; Reichardt P; Rutkowski P; Thomas D; Qian Y; Jacobs I, 2012, 'Efficacy and Safety of Denosumab in Giant Cell Tumor of Bone: Updated Results with Independent Radiographic Assessment of Response', Annals of Oncology, 23, pp. ix479 - ix479, http://dx.doi.org/10.1016/s0923-7534(20)34053-9

Thomas DM; Ballinger ML, 2012, 'Inherited and de novo germline TP53 mutations in adult-onset sarcoma', Hereditary cancer in clinical practice, 10, pp. A3 - A3, http://dx.doi.org/10.1186/1897-4287-10-s2-a3

Thomas DM; Ballinger ML, 2012, 'Inherited and de novo germline TP53 mutations in adult-onset sarcoma', Hereditary cancer in clinical practice, 10, pp. A26 - A26, http://dx.doi.org/10.1186/1897-4287-10-s2-a26

Mahendran K; Ballinger M; Kirk J; Thomas D; Tattersall M, 2012, 'Pathogenic germline TP53 mutations in adult sarcoma patients; implications for treatment and screening – description of an upcoming project', Hereditary cancer in clinical practice, 10, pp. A61 - A61, http://dx.doi.org/10.1186/1897-4287-10-s2-a61

Back to profile page